Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003142 DDI with Amiodarone and Febuxostat
NCT07181265Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Oct 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of JMKX003142 in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by Jemincare. Primary endpoints: Maximum Plasma Concentration at Steady State up to 7 days and Area Under the Curve Over the Dosing Interval up to 7 days. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
JMKX003142
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07181265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07181265.